Halo's lead program, H1614, is a small-molecule first-in-class inhibitor of hyaluronan (HA) synthesis.   H1614 is  a proprietary reformulation of 4-methylumbelliferone (4-MU) and the company has established a clear regulatory and intellectual property strategy to advance development.  

Our team's significant research and development efforts supporting the clinical potential of 4-MU include the results of a Phase 1 study and a Phase 2a proof of concept clinical trial, both completed at Stanford University.  

Phase 1

https://clinicaltrials.gov/study/NCT02780752

Phase 2a

https://clinicaltrials.gov/study/NCT05128929